Cytokinetics, Incorporated

Valuation Analysis

About the Company

Cytokinetics, Incorporated en bref

Cytokinetics, Incorporated (CYTK) is currently trading at 68,75 € with a market capitalization of 9,3 Md €. The 52-week range spans from 27,92 € to 69,99 €; the current price is 1.8% below the yearly high. Year-over-year revenue growth stands at +1125.8%.

💰 Dividende

Cytokinetics, Incorporated currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

20 analystes évaluent Cytokinetics, Incorporated (CYTK) au consensus : Acheter. L'objectif de cours moyen est de 91,37 €, soit un potentiel de +32.9% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 60,21 € à 127,41 €.

Cytokinetics, Incorporated : la thèse d'investissement en détail

Cytokinetics, Incorporated (CYTK) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 1125.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Buy with an average price target implying roughly 32.9% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 17.65% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The share is trading at 97.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
• The analyst consensus price target implies 32.9% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (17.65%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Cytokinetics, Incorporated?

Compare top-rated brokers — low fees, trusted providers, fully regulated.